Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#2014 Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study

Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rottenburger C, Nicolas G, McDougall L, Kaul F, Christ E,

Keywords: Medullary thyroid carcinoma, cholecystokinine-2 receptor, radionuclide therapy, theranostics,

#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: Radiolabelled somatostatin antagonist, PET, GEP-NET,

#1324 Somatostatin receptor PET/CT with radiolabelled antagonist is twice as effective as the agonist for detecting liver metastases: Results of a phase I/II study comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in gastro-entero-pancreatic neuroendocrine tumor p

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sst) expressing tumors (NET). Presence of liver metastases impacts on patient management and prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: somatostatin antagonist, PET,